- Home
- PRPO vs POAI Comparison
PRPO vs POAI Comparison
Compare PRPO & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- POAI
- Stock Information
- Founded
- PRPO N/A
- POAI 2002
- Country
- PRPO United States
- POAI United States
- Employees
- PRPO N/A
- POAI N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- POAI Industrial Specialties
- Sector
- PRPO Industrials
- POAI Health Care
- Exchange
- PRPO Nasdaq
- POAI Nasdaq
- Market Cap
- PRPO 17.1M
- POAI 8.9M
- IPO Year
- PRPO N/A
- POAI N/A
- Fundamental
- Price
- PRPO $15.75
- POAI $0.79
- Analyst Decision
- PRPO
- POAI Hold
- Analyst Count
- PRPO 0
- POAI 1
- Target Price
- PRPO N/A
- POAI N/A
- AVG Volume (30 Days)
- PRPO 16.9K
- POAI 159.3K
- Earning Date
- PRPO 08-12-2025
- POAI 08-12-2025
- Dividend Yield
- PRPO N/A
- POAI N/A
- EPS Growth
- PRPO N/A
- POAI N/A
- EPS
- PRPO N/A
- POAI N/A
- Revenue
- PRPO $20,029,000.00
- POAI $1,729,269.00
- Revenue This Year
- PRPO N/A
- POAI $486.27
- Revenue Next Year
- PRPO N/A
- POAI $65.50
- P/E Ratio
- PRPO N/A
- POAI N/A
- Revenue Growth
- PRPO 26.67
- POAI 24.17
- 52 Week Low
- PRPO $3.90
- POAI $0.55
- 52 Week High
- PRPO $16.89
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- PRPO 76.66
- POAI 33.09
- Support Level
- PRPO $10.60
- POAI $0.73
- Resistance Level
- PRPO $11.70
- POAI $0.86
- Average True Range (ATR)
- PRPO 0.97
- POAI 0.05
- MACD
- PRPO 0.45
- POAI -0.00
- Stochastic Oscillator
- PRPO 81.25
- POAI 38.43
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.